Alcon launches Voyager DSLT in US
- Alcon said on February 19, 2025 that Voyager DSLT is now fully commercially available in the U.S. for glaucoma and ocular hypertension treatment. - The pitch is automation: 120 laser pulses, no gonio lens, no manual aiming, and no contact with the eye during treatment. - It matters because glaucoma care is shifting toward first-line laser therapy, and Alcon now has a simpler way to deliver it.
Glaucoma treatment usually starts with a boring problem — daily eye drops that patients forget, dislike, or stop using. Laser treatment already existed as an alternative, but the standard version still asked a lot from the doctor and the patient. Alcon’s Voyager DSLT is the new twist. It takes a known glaucoma laser treatment and turns it into a non-contact, automated system now being sold across the U.S. (investor.alcon.com) ### What is Voyager actually doing? Voyager performs direct selective laser trabeculoplasty, or DSLT. The target is the trabecular meshwork — the drainage tissue that lets fluid leave the eye. I(investor.alcon.com)inage system. (myalcon.com) ### How is that different from regular SLT? Standard SLT is already familiar in glaucoma clinics, but it is hands-on. The doctor uses a gonio lens on the eye and manually aims treatment spots. Voyager’s whole selling point is that it removes that choreography. The device is designed to treat without a gonio lens, without manual aiming, a(myalcon.com)eep delivery on target. (investor.alcon.com) ### Why does “non-contact” matter so much? Because workflow is the bottleneck. Regular SLT works, but it can be fiddly — more like threading a needle than pressing a button. A non-contact system lowers the technical burden on the operator and may make it easier for more practices to offer laser earlier instead of defaulting to drops first. That is the strategic bet here, not just the engineering trick. (investor.alcon.com) ### Why is Alcon pushing first-line laser now? Because the evidence base has been moving that way for years. The LiGHT trial helped establish SLT as a clinically effective and cost-effective fir(investor.alcon.com)r than creating it from scratch. (thelancet.com) ### Where did this device come from? Alcon did not build the core idea from zero. It bought BELKIN Vision in July 2024, paying $81 million upfront, including about $65 million in cash, plus potential milestone payments. BELKIN had developed the DSLT platform before the acquisition. So the U.S. launch is really the commercialization phase of a technology Alcon bought to expand its glaucoma portfolio. (alcon.com) ### Who is this meant for? The company is positioning Voyager for patients with glaucoma and ocular hypertension — especially the huge group that could benefit from pressure lowering without the friction of daily drops. Alcon has framed the market in big terms, pointing to nearly 5 million Americans diagnosed with glaucoma and projecting growth to 6.3 million by 2050. (investor.alcon.com) ### What’s the catch? The catch is that easier delivery is not the same thing as universal adoption. Clinics still need to buy the device, fit it into reimbursement and workflow, and decide which patients should get DSLT versus drops, implantables, or conventional SLT. Voyager may widen access to first-line laser — but it still has to prove that convenience translates into routine use. (investor.alcon.com) ### Bottom line This launch matters because it tries to remove the awkward part of a treatment eye doctors already believe in. If Alcon’s automation really makes first-line laser simpler to deliver, Voyager could push glaucoma care a little further away from “here are your drops — good luck remembering them.” (investor.alcon.com)
